Fundraising FoxARCH Venture Partners — 2020 Investments
15 investments dated 2020 · listed companies and verified rows first · show all
Erasca is a clinical-stage oncology company developing therapies targeting RAS- and MAPK pathway-driven cancers using a modality-agnostic approach including small molecules, large molecules, and protein degraders.
BiotechDeep TechDigital HealthMedical DevicesSan Diego, US
Jonathan E. Lim, M.D.(Chairman, CEO and Co-founder)Gary Yeung, CFA(Chief Business Officer)in
BoardAlexander W. Casdin(Director)Pratik S. Multani, M.D.(Director)Valerie Harding-Start(Director)James A. Bristol, Ph.D.(Director)
PartnerKristina Burow· quoted
Co-investorsAndreessen HorowitzColt VenturesEvolution VC PartnersFrazier Life SciencesLifeSci Venture PartnersCity Hill Ventures+1 more
Aspen Neuroscience develops iPSC-derived autologous cell therapies for neurological diseases, with a lead product (ANPD001) in Phase 1/2a clinical trials for Parkinson's disease.
BiotechDeep TechDigital HealthMedical DevicesSan Diego, US
Andrés Bratt-Leal(Co-Founder and Senior Vice President, Research & Development)inANDRÉS BRATT-LEAL, Ph.D.(Co-Founder; Senior Vice President, Research & Development)Damien McDevitt(President and Chief Executive Officer)inDAMIEN MCDEVITT, Ph.D.(President and Chief Executive Officer)
Co-investorsLifeforce CapitalOrbiMedDomain AssociatesEDB InvestmentsSection 32Frazier Life Sciences+10 more
insitro is a drug discovery and development company that uses machine learning and cellular data to identify therapeutic insights and accelerate the creation of new medicines.
AI & Machine LearningBiotechSouth San Francisco, US
Daphne Koller(Founder)inDuane Valz(General Counsel)inMary Rozenman(Chief Financial Officer)in
BoardVijay Pande(Director)in
Board seatRobert Nelsen· per SEC Form D
Co-investorsAndreessen HorowitzDeviation CapitalForesite CapitalGV (Google Ventures)HOF CapitalSoftBank Vision Fund+9 more
Resilience is a contract development and manufacturing organization (CDMO) that manufactures complex pharmaceutical products and active pharmaceutical ingredients to broaden access to medicines and protect biopharmaceutical supply chains against disruption.
Advanced ManufacturingBiotechEnterprise SoftwareBlue Ash, US
William S. Marth(Chief Executive Officer)William S. Marth, RPh., MBA(President & CEO)
Board seatRobert Nelsen· per SEC Form D
Co-investors8VCCatalio Capital Management, LPGlobal Health Investment CorporationGV (Google Ventures)Koch Disruptive TechnologiesLux Capital+14 more
bit.bio is a synthetic biology company that engineers human induced pluripotent stem cells into defined cell types for research, drug discovery, and cell therapy applications.
BiotechDeep TechHealthtechMedical Devices
Dr Mark Kotter(Founder)Przemek Obloj(CEO)inEmma Pepperell(CEO)inMark Kotter(Founder)
Co-investorsForesite CapitalBlueYard CapitalDynamk CapitalGood AI CapitalHarmonix FundHAWKTAIL+7 more
Encoded develops gene therapies for neurological disorders through an integrated platform approach.
BiotechSouth San Francisco, US
Stephanie Tagliatela(Founder)inKartik Ramamoorthi, Ph.D.(Co-founder, Chief Executive Officer & Board Member)Kartik Ramamoorthi(Founder)
Co-investorsBioBritGV (Google Ventures)Illumina VenturesMenlo VenturesSoftBank Vision FundVenrock+2 more
EQRx was a Cambridge, MA biopharma that aimed to sell lower-priced novel drugs; it was acquired by Revolution Medicines in 2023.
Alexis Borisy(Founder)
Co-investorsAndreessen HorowitzArboretum VenturesGV (Google Ventures)Nextech InvestBain CapitalCasdin Capital+1 more
Cambridge, MA biotechnology company developing injectable synthetic biomarkers for noninvasive disease staging and treatment monitoring.
BiotechCambridge, US
Gabriel Kwong(Executive Officer)inSangeeta BhatiainRoopom Banerjee(Executive Officer)in
BoardTheresia Gouw(Director)inAmy Schulman(Director)Stan Lapidus(Director)in
Co-investorsGreatPoint VenturesAcrew CapitalAspect VenturesCatalio Capital ManagementCRV (Charles River Ventures)Dns Capital+7 more
Lyell develops CAR T-cell therapies for cancer patients by leveraging deep expertise in T-cell biology and oncology.
BiotechDeep TechHealthtechMedical DevicesBothell, US
Stan Riddell(Executive Officer)Richard Klausner(Executive Officer, Director, Promoter)Stephen Hill(Executive Officer)inHeather Turner(Executive Officer)inRichard Goold(Executive Officer)inMargo Roberts(Executive Officer)
Co-investorsForesite CapitalvenBio Partners8VCAxial VC
San Diego DNA sequencing company behind the Sequencing by Binding short-read platform; acquired by Pacific Biosciences in 2021.
BiotechSan Diego, US
David S. Mullarkey(Executive Officer, Director)Arnold Oliphant(Executive Officer)inKen Song, M.D., Ph.D.(Executive Officer, Director)Kelly Perez(Executive Officer)John Murphy, Ph.D.(Executive Officer)Millard Y Chan(Chief Operating Officer, Secretary and Director)
Co-investorsATEL VenturesDCVC (Data Collective)Decheng CapitalLam CapitalPivotal Life SciencesALTITUDE LIFE SCIENCE VENTURES+3 more
Boston-based biotech developing drugs against the 'dark genome'/repeatome for autoimmune disease, cancer and neurodegeneration.
Benjamin Greenbaum(Founder)David Ting(Founder)Rosana Kapeller(Founder)
Co-investorsAndreessen HorowitzGV (Google Ventures)Luma GroupSanofi VenturesAbingworthAdvent Life Sciences+11 more
SciNeuro develops targeted therapeutics for neurodegenerative and age-related brain diseases by integrating patient genetics, health history, and advanced diagnostic tools.
BiotechDeep TechDigital HealthLongevityMedical DevicesRockville, US
Min Li(CEO & Director)inSam Agus(CSO/CMO)Paul Stead(CBO)in
Co-investorsGeneral AtlanticLAV
Hong Kong-listed, Suzhou-headquartered biopharmaceutical company developing antibody therapeutics with in-house biomanufacturing.
Suzhou, CN
Xueming Qian(Executive Director, Chairman and CEO)in
Co-investorsChina Structural Reform FundFortune Venture CapitalHillhouse CapitalLilly Asia VenturesQatar Investment AuthorityTemasek
Walden Biosciences is a clinical-stage biotech company developing disease-modifying therapies that selectively target the kidney to treat the underlying drivers of kidney disease.
BiotechMedical Devices
Co-investorsATEM Capital FundPandect BioventuresUCB Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
SciNeuro
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.